Puma Biotechnology
(NASDAQ) PBYI
Puma Biotechnology Financials at a Glance
Market Cap
$412.79M
Revenue (TTM)
$227.18M
Net Income (TTM)
$24.38M
EPS (TTM)
$0.48
P/E Ratio
16.99
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$8.09
Volume
29,037
Open
$7.80
Price
$8.09
Volume
29,037
Open
$7.80
Previous Close
$8.09
Daily Range
$7.79 - $8.21
52-Week Range
$3.03 - $8.41
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$8.09
Volume
29,037
Open
$7.80
Previous Close
$8.09
Daily Range
$7.79 - $8.21
52-Week Range
$3.03 - $8.41
Estimated Earnings Date
Aug 6, 2026
PBYI News
PBYI: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Puma Biotechnology
Industry
Biotechnology
Sector
Health CareEmployees
179
CEO
Alan H. Auerbach
Website
www.pumabiotechnology.comHeadquarters
Los Angeles, CA 90024, US
PBYI Financials
Key Financial Metrics (TTM)
Gross Margin
74.46%
Operating Margin
12.98%
Net Income Margin
10.73%
Return on Equity
20.37%
Return on Capital
23.48%
Return on Assets
12.65%
Earnings Yield
5.89%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$412.79M
Shares Outstanding
50.90M
Volume
29.04K
Avg. Volume
282.64K
Financials (TTM)
Gross Profit
$169.15M
Operating Income
$29.49M
EBITDA
$44.91M
Operating Cash Flow
$53.61M
Capital Expenditure
-$10.00K
Free Cash Flow
$53.60M
Cash & ST Invst.
$101.55M
Total Debt
$15.95M
Puma Biotechnology Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$44.81M
-2.6%
Gross Profit
$34.39M
-3.0%
Gross Margin
76.74%
N/A
Market Cap
$412.79M
N/A
Market Cap/Employee
$2.40M
N/A
Employees
172
N/A
Net Income
-$3.75M
-226.2%
EBITDA
-$196.00K
-102.4%
Quarterly Fundamentals
Total Cash
$101.55M
+9.0%
Total Debt
$15.95M
-74.1%
Accounts Receivable
$26.33M
+4.6%
Inventory
$8.69M
-0.7%
Long Term Debt
$4.55M
-57.3%
Short Term Debt
$11.41M
-77.7%
Return on Assets
12.65%
N/A
Return on Invested Capital
22.18%
N/A
Free Cash Flow
$15.42M
+334.1%
Operating Cash Flow
$15.42M
+326.8%